OBJECTIVES: Several clinical trials have demonstrated that antithrombotic treatment may be effective in prevention of @entity64 in nonrheumatic @entity955 ( @entity955 ). The aim of this study was to assess if we follow clinical trial recommendations in community practice. METHODS: We analyzed 225 medical records of @entity1 diagnosed of @entity955 in C  ceres, during February and March 1998. @entity1 who were contraindicated to follow antiagreggation or anti-coagulation treatment were excluded. We compared @entity1 with and without antithrombotic treatment with different demographic characteristics and @entity887 factors. RESULTS: 205 @entity1 were included in the study, 149 (72.6%) had high @entity887 . 62 (30.2%) followed anticoagulation, 94 (45.8%) antiaggregation treatment, 5 (2.4%) both treatment and 49 (24%) were not receiving therapy. We didn't findings differences between age, sex, presence of @entity63 @entity299 , @entity101 and @entity712 in last three months compared with the @entity1 in respect to the group of patients with anticoagulation and antiaggregation therapy or without it. We determinate as well that previous @entity64 and echocardiographical finds ( @entity340 , @entity7874 , @entity67 ) were more frequent in the anticoagulation and antiaggregate @entity1 than in those without therapy. CONCLUSION: A high range of @entity955 @entity1 take any kind of antithrombotic preventive therapy, though a great number of @entity1 with high @entity887 could still get benefits from anticoagulation therapy. We should considerate in the therapy assessment some other clinical characteristics as @entity101 , isquemic @entity299 and @entity712 apart from echocardiographical findings.

[Antithrombotic treatment in non-rheumatic XXXX . Do we follow the recommendations of clinical trials?].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'heart failure'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysfunction'] @entity7874 :: ('MESH:C562942', 'Disease') :: ['valve calcification'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolic risk'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF', 'nonrheumatic AF'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease'] @entity340 :: ('MESH:D006349', 'Disease') :: ['valve disease']
@entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']
